New developments with umbilical cord blood

Bhakta, Shyam; Laughlin, M.J.

doi:10.1080/14653240801936306

Cited by 3 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CB is an alternative source for stem cell therapies beyond its usage in haematopoietic transplantation. There are many examples in the literature of the potential effects of CB stem cells in different models of disease (Körbling et al , 2005; Bhakta & Laughlin, 2008). Using this extra‐supply, CB banks can produce specific by‐products for cellular therapy.…”

Section: National Cb Bio‐resource For Researchmentioning

confidence: 99%

Cord blood banking: ‘providing cord blood banking for a nation’

et al. 2009

View full text Add to dashboard Cite

SummaryTransplantation of cord blood (CB) is increasingly used as therapy for patients whose own marrow is affected by genetic mutations that prevent the development of normal cells of the blood or immune tissues, or for patients whose marrow has been destroyed in the course of treatment for leukaemia and other malignancies. CB is a rich source of haematopoietic stem cells, can be easily harvested and stored in frozen aliquots in a CB bank. The first public CB bank was established in 1993 allowing unrelated CB transplantation to become an option for patients lacking a suitable adult donor. Today, the results of CB transplantation are comparable to those of bone marrow transplants with several important advantages: the graft is available 'off the shelf', thereby reducing the waiting time, and the requirements of human lecucoyte antigen (HLA) matching are less restrictive than those of adult sources. The reduced requirement for HLA matching allows transplants between incompletely matched donors and recipients, thus reducing the size of the inventory required at the national level. This also mitigates the disadvantage encountered by persons of rare HLA genotypes or those who do not belong to populations of North Western European descent. Finally, national CB programmes can easily make available for research individual surplus units not meeting minimal criteria for clinical use.

show abstract

Section: National Cb Bio‐resource For Researchmentioning

confidence: 99%

Cord blood banking: ‘providing cord blood banking for a nation’

et al. 2009

View full text Add to dashboard Cite

show abstract

“…12 Furthermore, it also opens new avenues for developing alternative transplantation therapies and novel non-haematopoietic applications. 13,14 During the past 20 years, outcomes of CBT progressively improved. [15][16][17][18] This was attributed to a combination of better clinical management and patient selection, development of standardized and novel clinical protocols and conditioning regimens, and overwhelmingly, especially in the adult setting, the increase in the number and quality of units offered, thus allowing transplantation of more cellular products with better match.…”

Section: Introductionmentioning

confidence: 99%

Quality rather than quantity: the cord blood bank dilemma

Querol

Gómez

Pagliuca

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

Growing inventories of cord blood units have facilitated access to umbilical cord cell transplantation for many patients lacking conventional stem cell donors. They are in principle 'off-the-shelf', 'fit-for-use', as well as safe and effective therapy products. Cellular enumeration is used as a surrogate of graft potency, and users rely on the rigorous assessment carried out in banks to avoid poor engraftment after thawing (loss of cells or poor function), when the patient's situation is critical. However, in practice, when units are selected, initially on the basis of HLA matching and cell dose assessment, their absolute quality remains uncertain. Unfortunately, quality-related issues (particularly related to viability) are not uncommon in cord blood transplantation. The reasons for potency failures are diverse, but a lack of thorough validation during critical steps of the process and of appropriate use of quality-control tools for timely detection of problematic units are significant contributors. Moreover, incongruence between different sets of standards and regulations, and lack of common quality systems between banks result in a highly heterogeneous international inventory. Therefore, this complicates the matter for the end user of the product. To ameliorate this situation, it is essential to improve quality at each of the critical manufacturing steps wherein potency can be threatened, thereby creating homogeneous inventories of units with excellent quality and quantity.

show abstract